Kura Oncology (KURA) announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib in the ongoing FIT-001 clinical trial of darlifarnib in combination with cabozantinib. In Cabozantinib-Pretreated patients, objective response rate was 44%, with a disease control rate of 94% across all doses tested in this population. Tumor was shrinkage observed in 75% of patients, with reductions ranging from 32% to 47% among responders. The company noted that these findings are notable given that patients who progress on cabozantinib are generally considered unlikely to respond to subsequent cabozantinib therapy.
"These data highlight the potential of darlifarnib to overcome resistance to prior cabozantinib and enhance the activity of VEGF TKIs in patients with advanced RCC," said Mollie Leoni, Chief Medical Officer of Kura Oncology.
In pre-market trading on NasdaqGS, Kura shares are up 5.9 percent to $9.47.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.